{'52WeekChange': 1.4714785,
 'SandP52WeekChange': 0.0644362,
 'address1': '128 Sidney Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 105.96,
 'askSize': 1000,
 'averageDailyVolume10Day': 904800,
 'averageVolume': 705833,
 'averageVolume10days': 904800,
 'beta': 0.739495,
 'beta3Year': None,
 'bid': 106.02,
 'bidSize': 1100,
 'bookValue': 7.732,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 110.62,
 'dayLow': 104.33,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -37.176,
 'enterpriseToRevenue': 70.463,
 'enterpriseValue': 5323961856,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 99.55315,
 'fiftyTwoWeekHigh': 110.75,
 'fiftyTwoWeekLow': 37.6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 47228417,
 'forwardEps': -2.81,
 'forwardPE': -37.775803,
 'fromCurrency': None,
 'fullTimeEmployees': 237,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.13502,
 'heldPercentInstitutions': 0.90094,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/acceleronpharma.com',
 'longBusinessSummary': 'Acceleron Pharma Inc., a clinical stage '
                        'biopharmaceutical company, focuses on the discovery, '
                        'development, and commercialization of therapeutics to '
                        'treat serious and rare diseases. Its therapeutic '
                        'candidates include luspatercept, which completed '
                        'Phase III clinical trials for the treatment of '
                        'myelodysplastic syndromes, beta-thalassemia, and '
                        'myelofibrosis; Phase II clinical trials for the '
                        'treatment of patients with transfusion-dependent '
                        'beta-thalassemia. The company is also developing and '
                        'sotatercept for the treatment of patients with '
                        'pulmonary hypertension. In addition, the company is '
                        'developing ACE-083, a neuromuscular candidate that is '
                        'in Phase II clinical trials for the treatment of '
                        'patients with facioscapulohumeral dystrophy and '
                        'Charcot-Marie-Tooth disease; and ACE-2494, which is '
                        'in Phase I clinical trials for the treatment of '
                        'systemic muscle disorders. It has a collaboration, '
                        'license, and option agreement with Celgene '
                        'Corporation; and collaboration and license agreement '
                        'with Fulcrum Therapeutics, Inc. to identify small '
                        'molecules designed to modulate specific pathways '
                        'associated with a targeted indication within the '
                        'pulmonary disease space. The company was formerly '
                        'known as Phoenix Pharma, Inc. Acceleron Pharma Inc. '
                        'was founded in 2003 and is headquartered in '
                        'Cambridge, Massachusetts.',
 'longName': 'Acceleron Pharma Inc.',
 'market': 'us_market',
 'marketCap': 6311254528,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_9004482',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -137744000,
 'nextFiscalYearEnd': 1640908800,
 'open': 110.62,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 649 9200',
 'previousClose': 110.25,
 'priceHint': 2,
 'priceToBook': 13.728661,
 'priceToSalesTrailing12Months': 83.52972,
 'profitMargins': -1.8230499,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 110.62,
 'regularMarketDayLow': 104.33,
 'regularMarketOpen': 110.62,
 'regularMarketPreviousClose': 110.25,
 'regularMarketPrice': 110.62,
 'regularMarketVolume': 633594,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 59419200,
 'sharesPercentSharesOut': 0.0623,
 'sharesShort': 3354504,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 3879374,
 'shortName': 'Acceleron Pharma Inc.',
 'shortPercentOfFloat': 0.0863,
 'shortRatio': 3.94,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'XLRN',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.598,
 'twoHundredDayAverage': 89.65849,
 'volume': 633594,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.acceleronpharma.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02139'}